February 22, 2018 / 1:46 PM / 4 months ago

BRIEF-Apellis Pharmaceuticals Announces 18-Month Results Of Phase 2 Study Of APL-2 In Geographic Atrophy

Reuters Staff

1 Min Read

Feb 22 (Reuters) - Apellis Pharmaceuticals Inc:

* APELLIS PHARMACEUTICALS ANNOUNCES 18-MONTH RESULTS OF PHASE 2 STUDY (FILLY) OF APL-2 IN GEOGRAPHIC ATROPHY Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.

0 : 0

narrow-browser-and-phone
medium-browser-and-portrait-tablet
landscape-tablet
medium-wide-browser
wide-browser-and-larger
medium-browser-and-landscape-tablet
medium-wide-browser-and-larger
above-phone
portrait-tablet-and-above
above-portrait-tablet
landscape-tablet-and-above
landscape-tablet-and-medium-wide-browser
portrait-tablet-and-below
landscape-tablet-and-below